Lactobacillus acidophilus CL1285 clinical trials
How each study uses lactobacillus acidophilus CL1285 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
In one entry with another drug
Given together, or one or the other
- Lactobacillus acidophilus CL1285 and Lactobacillus casei
- 2
Studies by the year they started
3 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2010 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lactobacillus acidophilus CL1285 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Evaluation of the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier PatientsWithdrawnPhase 2Bio-K Plus International Inc.NCT00941356Written as Bio-K+ CL1285
- BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile InfectionSuspendedPhase 3Bio-K Plus International Inc.NCT01202630Written as Lactobacillus acidophilus CL1285® and Lactobacillus casei
- Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult PatientsCompletedPhase 3Bio-K Plus International Inc.NCT00328263Written as Lactobacillus acidophilus CL1285 and Lactobacillus casei